Top

Published in:

01-02-2015 | Endocrine Tumors

Justified Follow-Up: A Final Intraoperative Parathyroid Hormone (ioPTH) Over 40 pg/mL is Associated with an Increased Risk of Persistence and Recurrence in Primary Hyperparathyroidism

Authors: Mohammad H. Rajaei, MD, Alex M. Bentz, David F. Schneider, MD, MS, Rebecca S. Sippel, MD, Herbert Chen, MD, Sarah C. Oltmann, MD

Published in: Annals of Surgical Oncology | Issue 2/2015

Abstract

Introduction

After parathyroidectomy for sporadic primary hyperparathyroidism (PHPT), overall rates of persistence/recurrence are extremely low. A marker of increased risk for persistence/recurrence is needed. We hypothesized that final intraoperative parathyroid hormone (FioPTH) ≥40 pg/mL is indicative of increased risk for disease persistence/recurrence, and can be used to selectively determine the degree of follow-up.

Method

A retrospective review of PHPT patients undergoing parathyroidectomy with ioPTH monitoring was performed. An ioPTH decline of 50 % was the only criteria for operation termination. Patients were grouped based on FioPTH of <40, 40–59, and >60 pg/mL.

Results

Between 2001 and 2012, 1,371 patients were included. Mean age was 61 ± 0.4 years, and 78°% were female. Overall persistence rate was 1.4°%, with a 2.9°% recurrence rate. Overall, 976 (71°%) patients had FioPTH < 40, 228 (16.6°%) had FioPTH 40–59, and 167 (12.2°%) had FioPTH ≥60. Mean follow-up was 21 ± 0.6 months. Patients with FioPTH <40 were younger, with lower preoperative serum calcium, PTH, and creatinine (all p ≤ 0.001). Patients with FioPTH <40 had the lowest persistence rate (0.2 %) versus patients with FioPTH 40–59 (3.5 %) or FioPTH ≥60 (5.4 %; p < 0.001). Recurrence rate was also lowest in patients with FioPTH <40 (1.3 vs. 5.9 vs. 8.2 %, respectively; p < 0.001). Disease-free status was greatest in patients with FioPTH <40 at 2 years (98.5 vs. 96.8 vs. 90.5 %, respectively) and 5 years (95.7 vs. 72.3 vs. 74.8 %, respectively; p < 0.01).

Conclusions

Patients with FioPTH < 40 pg/mL had lower rates of persistence and recurrence, than patients with FioPTH 40–59, or ≥60. Differences became more apparent after 2 years of follow-up. Patients with FioPTH ≥40 pg/mL warrant close and prolonged follow-up.

Clarke BL. Epidemiology of primary hyperparathyroidism. J Clin Densitom. 2013;16(1):8–13.PubMedCrossRef

Wang TS, Pasieka JL, Carty SE. Techniques of parathyroid exploration at North American endocrine surgery fellowship programs: what the next generation is being taught. Am J Surgery. 2014;207(4):527–532.CrossRef

Oltmann SC, Chen H. Minimally invasive radioguided parathyroidectomy. Curr Surg Reps. 2013;1(1):1–6.CrossRef

Hodin R, Angelos P, Carty S, et al. No need to abandon unilateral parathyroid surgery. J Am Coll Surg. 2012;215(2):297; author reply 297–300.PubMedCrossRef

Chen H, Mack E, Starling JR. A comprehensive evaluation of perioperative adjuncts during minimally invasive parathyroidectomy: which is most reliable? Ann Surg. 2005;242(3):375–380; discussion 380–373.PubMedCentralPubMed

Carneiro DM, Solorzano CC, Nader MC, Ramirez M, Irvin GL 3rd. Comparison of intraoperative iPTH assay (QPTH) criteria in guiding parathyroidectomy: which criterion is the most accurate? Surgery. 2003;134(6):973–979; discussion 979–981.PubMedCrossRef

Reiher AE, Schaefer S, Chen H, Sippel RS. Does the final intraoperative PTH level really have to fall into the normal range to signify cure? Ann Surg Oncol. 2012;19(6):1862–1867.PubMedCrossRef

Carneiro-Pla DM, Solorzano CC, Lew JI, Irvin GL. Long-term outcome of patients with intraoperative parathyroid level remaining above the normal range during parathyroidectomy. Surgery. 2008;144(6):989–993.PubMedCrossRef

Cook MR, Pitt SC, Schaefer S, Sippel R, Chen H. A rising ioPTH level immediately after parathyroid resection: are additional hyperfunctioning glands always present? An application of the Wisconsin Criteria. Ann Surg. 2010;251(6):1127–1130.PubMedCentralPubMedCrossRef

10.

Karakousis GC, Han D, Kelz RR, et al. Interpretation of intra-operative PTH changes in patients with multi-glandular primary hyperparathyroidism (pHPT). Surgery. 2007;142(6):845–850; discussion 850 e841–842.

11.

Richards ML, Thompson GB, Farley DR, Grant CS. An optimal algorithm for intraoperative parathyroid hormone monitoring. Arch Surg. 2011;146(3):280–285.PubMedCrossRef

12.

Chiu B, Sturgeon C, Angelos P. Which intraoperative parathyroid hormone assay criterion best predicts operative success? A study of 352 consecutive patients. Arch Surg. 2006;141(5):483–487; discussion 487–488.

13.

Schneider DF, Ojomo KA, Mazeh H, Oltmann SC, Sippel RS, Chen H. Significance of rebounding parathyroid hormone levels during parathyroidectomy. J Surg Res. 2013;184(1):265–268.PubMedCentralPubMedCrossRef

14.

Heller KS, Blumberg SN. Relation of final intraoperative parathyroid hormone level and outcome following parathyroidectomy. Arch Otolaryngol Head Neck Surg. 2009;135(11):1103–1107.PubMedCrossRef

15.

Wharry LI, Yip L, Armstrong MJ, et al. The final intraoperative parathyroid hormone level: how low should it go? World J Surg. 2014;38(3):558–563.PubMedCrossRef

16.

Irvin GL 3rd, Molinari AS, Figueroa C, Carneiro DM. Improved success rate in reoperative parathyroidectomy with intraoperative PTH assay. Ann Surg. 1999;229(6):874–878; discussion 878–879.PubMedCentralPubMedCrossRef

17.

Yen TW, Wang TS. Subtotal parathyroidectomy for primary hyperparathyroidism. Endocrine Pract. 2011;17 Suppl 1:7–12.CrossRef

18.

Pathak PR, Holden SE, Schaefer SC, Leverson G, Chen H, Sippel RS. Elevated parathyroid hormone after parathyroidectomy delays symptom improvement. J Surg Res. 2014;190(1):119–125.PubMedCentralPubMedCrossRef

19.

Morris LF, Zanocco K, Ituarte PH, et al. The value of intraoperative parathyroid hormone monitoring in localized primary hyperparathyroidism: a cost analysis. Ann Surg Oncol. 2010;17(3):679–685.PubMedCentralPubMedCrossRef

20.

Leiker AJ, Yen TW, Eastwood DC, et al. Factors that influence parathyroid hormone half-life: determining if new intraoperative criteria are needed. JAMA Surg. 2013;148(7):602–606.PubMedCrossRef

21.

Gannage-Yared MH, Abboud B, Amm-Azar M, et al. Predictors of intra-operative parathyroid hormone decline in subjects operated for primary hyperparathyroidism by minimally invasive parathyroidectomy. J Endocrinol Invest. 2009;32(2):160–164.PubMedCrossRef

22.

Carsello CB, Yen TW, Wang TS. Persistent elevation in serum parathyroid hormone Levels in normocalcemic patients after parathyroidectomy: does it matter? Surgery. 2012;152(4):575–581; discussion 581–573.PubMedCrossRef

23.

Untch BR, Barfield ME, Dar M, Dixit D, Leight GS Jr, Olson JA Jr. Impact of 25-hydroxyvitamin D deficiency on perioperative parathyroid hormone kinetics and results in patients with primary hyperparathyroidism. Surgery. 2007;142(6):1022–1026.PubMedCrossRef

24.

Wang TS, Ostrower ST, Heller KS. Persistently elevated parathyroid hormone levels after parathyroid surgery. Surgery. 2005;138(6):1130–1135; discussion 1135–1136.PubMedCrossRef

25.

Beyer TD, Solorzano CC, Prinz RA, Babu A, Nilubol N, Patel S. Oral vitamin D supplementation reduces the incidence of eucalcemic PTH elevation after surgery for primary hyperparathyroidism. Surgery. 2007;141(6):777–783.PubMedCrossRef

Title: Justified Follow-Up: A Final Intraoperative Parathyroid Hormone (ioPTH) Over 40 pg/mL is Associated with an Increased Risk of Persistence and Recurrence in Primary Hyperparathyroidism
Authors: Mohammad H. Rajaei, MD
Alex M. Bentz
David F. Schneider, MD, MS
Rebecca S. Sippel, MD
Herbert Chen, MD
Sarah C. Oltmann, MD
Publication date: 01-02-2015
Publisher: Springer US
Published in: Annals of Surgical Oncology / Issue 2/2015
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-014-4006-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Justified Follow-Up: A Final Intraoperative Parathyroid Hormone (ioPTH) Over 40 pg/mL is Associated with an Increased Risk of Persistence and Recurrence in Primary Hyperparathyroidism

Abstract

Introduction

Method

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Method

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2015

The Role of Ultrasound-Guided Lymph Node Biopsy in Axillary Staging of Invasive Breast Cancer in the Post-ACOSOG Z0011 Trial Era

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Carcinoma: Analysis of 30-Day Morbidity and Mortality

Assessing Safety and Outcomes in Outpatient versus Inpatient Thyroidectomy using the NSQIP: A Propensity Score Matched Analysis of 16,370 Patients

Tumor Size as a Recommendable Variable for Accuracy of the Prognostic Prediction of Gastric Cancer: A Retrospective Analysis of 1,521 Patients

In-transit Melanoma Metastases: Incidence, Prognosis, and the Role of Lymphadenectomy

Does the Extent of Resection Impact Survival for Duodenal Adenocarcinoma? Analysis of 1,611 Cases